

## **ASX** Release

### Eastland Moves to 100% in Star Medical Botswana

**Eastland Medical Systems Ltd (ASX:EMS)** advises that it has now increased its stake in the African drug development company, Star Medical (Botswana) Limited (Star) to 100% by acquiring the interests of another shareholder on the same terms and conditions as in previous arrangements.

Star holds the exclusive rights to the Intellectual Property for the patented sub-lingual anti malaria treatment ArTiMist™ for Africa.

#### Further information:

Dermot Patterson CEO and Company Secretary Eastland Medical Systems Ltd t: +61 (0) 8 9436 9500 www.eastlandmedical.com.au

# Highlights

- Phase 1 multidose clinical trials for ArTiMist<sup>TM</sup> were undertaken in South Africa in February 2008 with positive results indicating the formulation was well tolerated and showed no adverse effects in any of the trial subjects.
- Eastland<sup>®</sup> is now moving to Clinical Field Trials and Regulatory Approval.

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002.

		c		. •	
am	0	$\alpha$ t	an	111	ŀ۲

### EASTLAND MEDICAL SYSTEMS LTD

ABN

35 090 987 250

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- Fully paid ordinary shares.
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued.
- 1,266,667 (One million two hundred & sixty six thousand six hundred & sixty seven) shares
- 3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- Same terms as existing Fully Paid ordinary shares ranking equally in all respects.
- 4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes. Shares rank equally with all other ordinary fully paid shares from date of allotment.

<sup>+</sup> See chapter 19 for defined terms.

5	Issue price or consideration	1,266,667 Ordinary Fully Paid Shares at \$0.30 cents per share for a value of \$380,000 in terms of those agreements.		
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Securities issued in consideration for increased share holding in Star Medical Botswana Limited in terms of Sale Agreements.		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	17th September, 2009		
		Number	+Class	
8	Number and +class of all +securities	351,624,351	Fully paid ordinary shares.	
	quoted on ASX (including the securities in clause 2 if applicable)	47,586,231	Ordinary Options exercisable at \$0.20 cents expiring 31 May 2011	
		43,558,905	Ordinary Options exercisable at \$0.10 cents expiring 30 June 2011	
		Number	+Class	
9	Number and +class of all +securities	750,000		
	not quoted on ASX ( <i>including</i> the securities in clause 2 if applicable)	6,000,000	maturing 30 June 2012	
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Available	to participate from date of issue	
	Part 2 - Bonus issue or	r pro rata	issue	
11	Is security holder approv required?	al N/a		
12	Is the issue renounceable or no renounceable?	n- N/a		
13	Ratio in which the *securities w be offered	ill N/a		
14	*Class of *securities to which the offer relates	he N/a		
15	<sup>+</sup> Record date to determinentitlements	ne N/a		
16	Will holdings on different registe (or subregisters) be aggregated for calculating entitlements?			

Policy for deciding entitlements in N/a relation to fractions

17

18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with. Cross reference:	N/a
19	rule 7.7.  Closing date for receipt of acceptances or renunciations	N/a
20	Names of any underwriters	N/a
21	Amount of any underwriting fee or commission	N/a
22	Names of any brokers to the issue	N/a
23	Fee or commission payable to the broker to the issue	N/a
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/a
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/a
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/a
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/a
28	Date rights trading will begin (if applicable)	N/a
29	Date rights trading will end (if applicable)	N/a
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/a
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/a
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/a
33	<sup>+</sup> Despatch date	N/a

# Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities

11/3/2002 Appendix 3B Page 3

34	Type of securities (tick one)
(a)	√ Securities described in Part 1
(b)	All other securities
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entit	ies that have ticked box 34(a)
Addit	ional securities forming a new class of securities
(If the a	dditional securities do not form a new class, go to 43)
Tick to docume	indicate you are providing the information or nts
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000
	1,001 - 5,000 5,001 - 10,000
	10,001 - 100,000
	100,001 and over
37	A copy of any trust deed for the additional *securities

(now go to 43) Entities that have ticked box 34(b) Number of securities for which N/a +quotation is sought 39 Class of +securities for which N/a quotation is sought 40 Do the \*securities rank equally in all N/a respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation N/a now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) Number +Class 42 Number and +class of all +securities N/a quoted on ASX (including the securities in clause 38) (now go to 43) All entities Food

43	Payme	ent method (tick one)
6		Cheque attached
		Electronic payment made  Note: Payment may be made electronically if Appendix 3B is given to ASX electronically at the same time.
		Periodic payment as agreed with the home branch has been arranged  Note: Arrangements can be made for employee incentive schemes that involve frequent issues of securities.

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that noone has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are true and complete.

== == == ==

Sign here:

Company Secretary

Print name: Dermot Patterson

Date: 17th September, 2009.